BDR Pharmaceuticals is in discussions to acquire manufacturing assets worth $100 million in the United States, aiming to strengthen its presence in the lucrative U.S. market. The company, which is backed by multiples and has revenues of around $200 million, is currently evaluating several potential units and is in the due diligence phase.
“We expect to make a decision regarding the asset acquisition, which could involve an investment of around $100 million, in the next three to four months,” said Dharmesh Shah, Chairman and Managing Director of BDR Pharmaceuticals.
Focus on U.S. Market and Strategic Acquisitions for Growth
The Mumbai-based pharmaceutical company is significantly ramping up its investments, particularly in the U.S. market, to fuel its growth trajectory. Shah highlighted that the acquisition would help BDR locally manufacture controlled substances and complex molecules. This move is driven partly by the U.S. government’s preference for local producers, a shift reinforced by President Donald Trump’s push for domestic manufacturing.
“Despite the high operating costs, Indian companies are increasingly looking at setting up local units to avoid tariff uncertainties and tap into U.S. government programs like Medicaid and Medicare,” Shah noted.
Capital Investments and Expansion Plans
BDR has made significant capital expenditures to support its expansion. Over the past three to four years, the company has invested nearly ₹600 crore and plans to allocate an additional ₹700 crore in the next two to three years. The investment strategy includes both organic growth and inorganic acquisitions. The company has funded this aggressive expansion entirely through internal accruals, adhering to its zero-borrowing policy.
U.S. Market Expansion and Upcoming Product Launches
BDR Pharmaceutical is set to launch its first product in the U.S. by the last quarter of 2026. The company is also preparing for U.S. Good Manufacturing Practices (GMP) inspections at two of its Indian facilities, scheduled for October and November.
Additionally, BDR is actively acquiring a large portfolio of abbreviated new drug applications (ANDAs) in a multi-million dollar deal. These ANDAs will cover a variety of product types, including solid dosage, injectables, and dermatology, with therapeutic areas such as cardiology, diabetology, pain management, and oncology. “We plan to transfer at least ten of these acquired ANDAs to India by the end of the year and start production,” Shah shared.
Strengthening Global Presence with Strategic Assets
Alongside its U.S. expansion, BDR Pharma is establishing an oncology unit in Algeria and is in negotiations to acquire an asset in Kazakhstan, also focused on oncology and complex injectables. In India, BDR continues to expand its manufacturing capacity, with plans to set up new production units to meet growing demand.
Export Growth and R&D Investments
Exports currently account for 50% of BDR Pharma’s revenue, and the company has set a goal to increase this figure to 70% over the next two years. Shah emphasized that the company’s focus on complex, technology-driven products and backward integration will be a key differentiator in competitive markets like the U.S. BDR Pharma is investing heavily in research and development (R&D).
A new R&D center is establishing in Padra, Gujarat, focusing on API synthesis, including oligonucleotides and peptides. The company is also working on new drug delivery systems to reduce toxicity and enhance bioavailability, particularly in oncology.
Strategic Partnerships and Future Outlook
Alongside marketing drugs under its own brand, BDR also licenses its medicines to other major Indian pharma players. The company has built a reputation for its complex injectables, particularly for treating bacterial and fungal infections, pain, and cancers. Moneycontrol.com reports that BDR Pharmaceuticals’ forward-looking approach to acquisitions, expansion, and R&D positions it for strong growth, particularly in international markets like the U.S.
